Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Wulf, G.
1045  Ergebnisse:
Personensuche X
?
1

Drug monitoring during ciprofloxacin prophylaxis of allogen..:

Kaba, H.E.J. ; Hasenkamp, J. ; Tas, H....
Journal of Hospital Infection.  143 (2024)  - p. 160-167 , 2024
Link: https://doi.org/10.1016/..
 
?
2

REAL-WORLD DATA SUGGEST EFFECTIVNESS OF THE ALLOGENEIC MESE..:

Pfeffermann, L. ; Boenig, H.B. ; Verbeek, M....
Cytotherapy.  26 (2024)  6 - p. S24 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Prognostic factors for cellular therapies ‐ CART and alloge..:

Glass, B. ; Sureda, A. ; Boumendil, A....
Hematological Oncology.  41 (2023)  S2 - p. 449-451 , 2023
Link: https://doi.org/10.1002/..
 
?
4

Axicabtagene ciloleucel (Axicel) for relapsed/refractory pr..:

Schubert, M. ; Ayuk, F. A. ; Bethge, W....
Hematological Oncology.  41 (2023)  S2 - p. 411-412 , 2023
Link: https://doi.org/10.1002/..
 
?
5

Efficacy and toxicity of CAR T‐cell therapy in patients wit..:

Laube, A. ; Fuhrmann, S. ; Peczynski, C....
Hematological Oncology.  41 (2023)  S2 - p. 454-456 , 2023
Link: https://doi.org/10.1002/..
 
?
6

Allogeneic transplantation in T‐cell lymphoma: Lessons from..:

Tournilhac, O. ; Altmann, B. ; Friedrichs, B....
Hematological Oncology.  41 (2023)  S2 - p. 512-513 , 2023
Link: https://doi.org/10.1002/..
 
?
7

Randomized phase-III study of low-dose cytarabine and etopo..:

Schlenk, R. F. ; Weber, D. ; Krzykalla, J....
Scientific Reports.  13 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
8

P448: PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATI..:

Ruecker, F. G. ; Corbacioglu, A. ; Theis, F....
HemaSphere.  6 (2022)  - p. 348-349 , 2022
Link: https://doi.org/10.1097/..
 
?
9

S106: UBTF-ATXN7L3 GENE FUSION DUE TO 17Q21.31 DELETION DEF..:

Bastian, L. ; Hartmann, A. ; Beder, T....
HemaSphere.  6 (2022)  - p. 7-8 , 2022
Link: https://doi.org/10.1097/..
 
?
10

S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 S..:

Sureda, A. ; Westin, J. ; Locke, F. L....
HemaSphere.  6 (2022)  - p. 112-113 , 2022
Link: https://doi.org/10.1097/..
 
?
11

P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THER..:

Derigs, P. ; Bethge, W. ; Holtick, U....
HemaSphere.  6 (2022)  - p. 1331-1332 , 2022
Link: https://doi.org/10.1097/..
 
?
12

Hypernatriämie und Polyurie bei einer Patientin mit Erstdia..:

Aydilek, E. ; Jäger, K. ; Xhaxho, K....
Die Innere Medizin.  63 (2022)  11 - p. 1194-1199 , 2022
Link: https://doi.org/10.1007/..
 
?
13

OUTCOME DETERMINANTS OF COMMERCIAL CAR‐T CELL THERAPY FOR L..:

Dreger, P. ; Martus, P. ; Holtick, U....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
14

FIRST‐LINE THERAPY OF T‐CELL LYMPHOMA: ALLOGENEIC OR AUTOLO..:

Tournilhac, O. ; Truemper, L. ; Ziepert, M....
Hematological Oncology.  37 (2019)  S2 - p. 99-101 , 2019
Link: https://doi.org/10.1002/..
 
?
15

EBMT prospective observational study on allogeneic hematopo..:

Wiktor-Jedrzejczak, W. ; Drozd-Sokolowska, J. ; Eikema, D. J....
Bone Marrow Transplantation.  54 (2019)  9 - p. 1391-1398 , 2019
Link: https://doi.org/10.1038/..
 
1-15